Sublingual misoprostol versus standard surgical care for treatment of incomplete abortion in five sub-Saharan African countries

Tara Shochet, Ayisha Diop, Alioune Gaye, Madi Nayama, Aissata Bal Sall, Fawole Bukola, Thieba Blandine, Okunlola Michael Abiola, Blami Dao, Ogunbode Olayinka, Beverly Winikoff, Tara Shochet, Ayisha Diop, Alioune Gaye, Madi Nayama, Aissata Bal Sall, Fawole Bukola, Thieba Blandine, Okunlola Michael Abiola, Blami Dao, Ogunbode Olayinka, Beverly Winikoff

Abstract

Background: In low-resource settings, where abortion is highly restricted and self-induced abortions are common, access to post-abortion care (PAC) services, especially treatment of incomplete terminations, is a priority. Standard post-abortion care has involved surgical intervention but can be hard to access in these areas. Misoprostol provides an alternative to surgical intervention that could increase access to abortion care. We sought to gather additional evidence regarding the efficacy of 400 mcg of sublingual misoprostol vs. standard surgical care for treatment of incomplete abortion in the environments where need for economical non-surgical treatments may be most useful.

Methods: A total of 860 women received either sublingual misoprostol or standard surgical care for treatment of incomplete abortion in a multi-site randomized trial. Women with confirmed incomplete abortion, defined as past or present history of vaginal bleeding during pregnancy and an open cervical os, were eligible to participate. Participants returned for follow-up one week later to confirm clinical status. If abortion was incomplete at that time, women were offered an additional follow-up visit or immediate surgical evacuation.

Results: Both misoprostol and surgical evacuation are highly effective treatments for incomplete abortion (misoprostol: 94.4%, surgical: 100.0%). Misoprostol treatment resulted in a somewhat lower chance of success than standard surgical practice (RR = 0.90; 95% CI: 0.89-0.92). Both tolerability of side effects and women's satisfaction were similar in the two study arms.

Conclusion: Misoprostol, much easier to provide than surgery in low-resource environments, can be used safely, successfully, and satisfactorily for treatment of incomplete abortion. Focus should shift to program implementation, including task-shifting the provision of post-abortion care to mid- and low- level providers, training and assurance of drug availability.

Trial registration: This study has been registered at clinicaltrials.gov as NCT00466999 and NCT01539408.

Figures

Figure 1
Figure 1
Study flowchart.

References

    1. World Health Organization (WHO) Unsafe abortion: Global and regional estimates of the incidence of unsafe abortion and associated mortality in 2008. 6. Geneva: WHO; 2011.
    1. Weeks A, Alia G, Blum J, Winikoff B, Ekwaru P, Durocher J, Mirembe F. A randomized trial of misoprostol compared with manual vacuum aspiration for incomplete abortion. Obstet Gynecol. 2005;106(3):540–547. doi: 10.1097/01.AOG.0000173799.82687.dc.
    1. Shwekerela B, Kalumuna R, Kipingili R, Mashaka N, Westheimer E, Clark W, Winikoff B. Misoprostol for treatment of incomplete abortion at the regional hospital level: Results from Tanzania. BJOG. 2007;114(11):1363–1367. doi: 10.1111/j.1471-0528.2007.01469.x.
    1. Dao B, Blum J, Thieba B, Raghavan S, Ouedraego M, Lankoande J, Winikoff B. Is misoprostol a safe, effective and acceptable alternative to manual vacuum aspiration for post-abortion care? Results from a randomized trial in Burkina Faso, West Africa. BJOG. 2007;114(11):1368–1375. doi: 10.1111/j.1471-0528.2007.01468.x.
    1. Bique C, Ustá M, Debora B, Chong E, Westheimer E, Winikoff B. Comparison of misoprostol and manual vacuum aspiration for the treatment of incomplete abortion. Int J Gynaecol Obstet. 2007;98(3):222–226. doi: 10.1016/j.ijgo.2007.05.003.
    1. Blum J, Winikoff B, Gemzell-Danielsson K, Ho PC, Schiavon R, Weeks A. Treatment of incomplete abortion and miscarriage with misoprostol. Int J Gynaecol Obstet. 2007;99(Suppl 2):S186–S189.
    1. Diop A, Raghavan S, Rakotovao JP, Comendant R, Blumenthal PD, Winikoff B. Two routes of administration for misoprostol in the treatment of incomplete abortion: a randomized clinical trial. Contraception. 2009;79(6):456–462. doi: 10.1016/j.contraception.2008.11.016.
    1. Dabash R, Ramadan MC, Darwish E, Hassanein N, Blum J, Winikof B. A randomizes controlled trial of 400-μg sublingual misoprostol versus manual vacuum aspiration for the treatment of incomplete abortion in two Egyptian hospitals. Int J Gynaecol Obstet. 2010;111(2):131–135. doi: 10.1016/j.ijgo.2010.06.021.
    1. Taylor J, Diop A, Blum J, Dolo O, Winikoff B. Oral misoprostol as an alternative to surgical management for incomplete abortion in Ghana. Int J Gynaecol Obstet. 2011;112(1):40–44. doi: 10.1016/j.ijgo.2010.08.022.
    1. Akin A, Blum J, Ozalp S, Onderoğlu L, Kirca U, Bilgili N, Koçoğlu G, Philip N, Winikoff B. Results and lessons learned from a small medical abortion clinical study in Turkey. Contraception. 2004;70(5):401–406. doi: 10.1016/j.contraception.2004.05.005.
    1. Akin A, Dabash R, Dilbaz B, Aktün H, Dursun P, Kiran S, Aksan G, Doğan B, Winikoff B. Increasing women’s choices in medical abortion: a study of misoprostol 400 microg swallowed immediately or held sublingually. Eur J Contracept Reprod Health Care. 2009;14(3):169–175. doi: 10.1080/13625180902916020.
    1. Grossman D, Ellertson C, Grimes DA, Walker D. Routine follow-up visits after first-trimester induced abortion. Obstet Gynecol. 2004;103(4):738–745. doi: 10.1097/01.AOG.0000115511.14004.19.
    1. Fjerstad M. Figuring out follow-up. Mifematters PPFA/CAPS. 2006;13:2–3.
    1. American College of Obstetricians and Gynecologists. Misoprostol for postabortion care. ACOG Committee Opinion No. 427. Obstet Gynecol. 2009;113:465–468.
    1. World Health Organization. Safe abortion: Technical and policy guidance for health systems. 2. Geneva: WHO; 2012.
    1. World Health Organization (WHO) WHO model list of essential medicines. 16. Geneva: WHO; 2010.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅